Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administrations Adverse Event Reporting System (FAERS) regarding suspected adverse events of AP linked to GLP-1 RAs from January 2005 to September 2023
Louis University Hospital
And if a patient meets their goalsloses weight, improves blood sugar, blood pressure, or cholesterolwe may even de-escalate therapy by lowering the semaglutide dose or switching to liraglutide to prevent excess weight loss, which can come at the expense of muscle mass. Overall, switching works best when its intentional and coordinated with your physician
Theres multiple states that have passed legislation that require transparency about how much money is collected by the insurers and the PBMs funded by pharmaceutical industry and how much is passed back on to the plans sponsor or to patients, State of Texas comes to mind
This repositions pharmaceutical intervention not as a last resort, but as a core component of obesity managementraising questions about how this will influence long-term consumer behavior